<DOC>
	<DOC>NCT02278978</DOC>
	<brief_summary>BIBF1120 in patients with advanced FGFR3 mutated, FGFR3 overexpressed, or FGFR3 wild type urothelial carcinoma of urinary bladder, urethra, ureter, and renal pelvis and who have failed platinum-based chemotherapy.</brief_summary>
	<brief_title>BIBF1120 in Patients With Advanced FGFR3 Mutated,Overexpressed,or Wild Type Urothelial Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma, Transitional Cell</mesh_term>
	<mesh_term>Nintedanib</mesh_term>
	<criteria>KPS 60% Histological confirmation of urothelial carcinoma , with metastatic disease Measurable disease Previously treated with platinumbased chemotherapy administered Radiographic evidence of cavitary or necrotic tumours Active brain metastasis.Leptomeningeal metastasis Chemotherapy, radiotherapy, targeted therapy with monoclonal antibodies or small tyrosine kinase inhibitors Grade 1 treatmentrelated toxicity from previous chemotherapy, radiotherapy, or targeted therapy Prior treatment with BIBF 1120 or other VEGFR inhibitors Significant cardiovascular diseases: Pericardial effusion Significant bleeding or thrombosis Gastrointestinal disorders or abnormalities that would interfere with absorption of the study drug Major injuries within the past 10 days with incomplete wound healing and/or planned surgery during the ontreatment study period</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>urothelial carcinoma</keyword>
	<keyword>BIBF1120</keyword>
</DOC>